Climb Bio (CLYM) Cash from Investing Activities (2020 - 2026)

Climb Bio's Cash from Investing Activities history runs 7 years deep, the most recent figure standing at -$13.0 million for Q1 2026.

• Quarterly Cash from Investing Activities rose 69.7% year-over-year to -$13.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $32.6 million (up 118.37% YoY) and the FY2025 annual result came in at $2.8 million, up 102.34% from the prior year.
• Cash from Investing Activities was -$13.0 million for Q1 2026 at Climb Bio, down from $25.5 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $36.7 million in Q4 2023 and bottomed at -$71.8 million in Q3 2024.
• A 5-year average of -$1.6 million and a median of $5.8 million in 2023 frame the typical range for Cash from Investing Activities.
• Annual changes were most pronounced in 2022 — Cash from Investing Activities jumped 277.34% — and 2024, when it slumped 502.44%.
• Climb Bio's Cash from Investing Activities stood at $14.3 million in 2022, then soared by 157.37% to $36.7 million in 2023, then tumbled by 245.34% to -$53.4 million in 2024, then surged by 147.82% to $25.5 million in 2025, then sank by 150.73% to -$13.0 million in 2026.
• Business Quant data shows CLYM's Cash from Investing Activities at -$13.0 million in Q1 2026, $25.5 million in Q4 2025, and $15.3 million in Q3 2025.